Overexpression of HER2, resulting from amplification of the ErbB2 gene, is observed in approximately 20% of breast cancers, and amplification of HER2 significantly correlates with increased disease aggressiveness and thereby with poor patient outcome [2], [3], [4], [5], [6]. Here, ERBB2 is linked to breast cancer.